Core Viewpoint - The seventh Xinhui Chenpi Cultural Festival emphasizes the theme of "Xinhui Chenpi, Shared by Humanity," showcasing the high-quality development of the Xinhui Chenpi industry and establishing a significant platform for production and sales connections [2][3]. Group 1: Industry Development - The Xinhui Chenpi industry has consistently adhered to the principles of open collaboration, mutual benefit, and win-win outcomes, responding actively to national calls for East-West cooperation [10][11]. - The collaboration between Xinhui and Ningming aims to integrate Xinhui's industrial advantages with Ningming's resource endowments, creating a comprehensive industrial chain [12][13]. Group 2: Product Innovation - The "Chenpi Star Oil Vine Tea" series represents a deep integration of the industrial value of Xinhui Chenpi and the health resources of Ningming's "plant brain gold" star oil vine, based on a clear "complementary" logic [15][16]. - The collaboration has established a complete industrial chain from "Ningming planting—Bay Area empowerment—national sales," involving over 12,000 households in Ningming cultivating 60,000 acres of star oil vine, with each household potentially increasing annual income by 15,000 to 40,000 yuan [24][29]. Group 3: Collaborative Framework - The "Four Sharing" model has been innovatively constructed to enhance product quality and market access through shared research platforms, production standards, market channels, and storage resources [17][18][39]. - The collaboration has led to significant economic impacts, with a cumulative sales amount of 235 million yuan for agricultural products, and the establishment of a cooperative model involving enterprises, cooperatives, and farmers [32][24]. Group 4: Cultural and Educational Initiatives - Cultural collaboration is also deepening, with the establishment of the "Xinhui-Ningming Jing Tang Library," promoting cultural enrichment and rural civilization [34][36]. - The Xinhui Ningming work group has invited national channel merchants and entrepreneurs to explore the "Chenpi+" product development and promotion, aiming to jointly tap into the vast potential of the health industry [43][45].

Core Points - Company Marubi Biotechnology (603983) submitted an application for H-share issuance and listing to the Hong Kong Stock Exchange on December 11, 2025, with the application materials published on the exchange's website on the same day [1] Issuance Arrangement - The issuance is limited to specific investor groups, including Hong Kong public investors, qualified overseas investors, and domestic qualified investors eligible for overseas securities investment [2] - The listing will take place on the main board of the Hong Kong Stock Exchange [2] - The application materials are in draft form and may be updated or revised, pending approval from regulatory bodies such as the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange [2] - The company has provided links to the application materials in both Chinese and English on the Hong Kong Stock Exchange website for domestic investors to access relevant information [2]

Core Viewpoint - Marubi Biotechnology (603983.SH) has submitted an application for the issuance of H-shares and listing on the Hong Kong Stock Exchange on December 11, 2025 [1] Group 1 - The company has officially filed its application with the Hong Kong Stock Exchange [1] - The application materials for the issuance and listing have been published on the Hong Kong Stock Exchange's website [1]

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 从资金流向上来看，当日化妆品板块主力资金净流出8756.28万元，游资资金净流入472.66万元，散户资 金净流入8283.61万元。化妆品板块个股资金流向见下表： 证券之星消息，12月12日化妆品板块较上一交易日下跌0.34%，嘉亨家化领跌。当日上证指数报收于 3889.35，上涨0.41%。深证成指报收于13258.33，上涨0.84%。化妆品板块个股涨跌见下表： ...

Core Viewpoint - The IPO of Plant Doctor, a company focused on high-altitude plant skincare and a single-brand chain model, reflects a significant shift in the Chinese cosmetics industry towards brand value and sustainable business models after a period of intense competition and marketing frenzy [1] Group 1: Company Overview - Plant Doctor has over 30 years of experience and integrates traditional wisdom from the Naxi culture into its modern brand strategy, emphasizing "high-altitude plants for pure skin" [3] - The company has established a robust research and development network, collaborating with the Kunming Institute of Botany since 2014, and has created a global R&D network with five bases [3] - Plant Doctor has developed a core ingredient, "Dendrobium oligosaccharides," through extensive research on high-altitude plants, which has led to market success for its flagship product line [3] Group 2: Business Model - The company focuses on a single-brand chain model, maintaining over 4,200 stores globally, which enhances brand experience and customer trust [4] - This model creates significant channel control and operational efficiencies, supported by a large network that provides valuable consumer data for product development [4] - Plant Doctor has been recognized as a leading single-brand skincare store by Euromonitor International for three consecutive years, validating the effectiveness of its business model [4] Group 3: Market Context - The cosmetics industry is moving away from rapid expansion driven by traffic and price competitiveness, with increasing pressure from homogenization and profit margins [5] - Investors and consumers are now favoring brands with clear differentiation, solid technological foundations, and sustainable profit models [5] Group 4: IPO and Future Prospects - The funds raised from the IPO will be used to enhance R&D and upgrade the global store network, reinforcing the company's competitive advantages [6] - The successful expansion into markets like Japan and Thailand demonstrates the cross-cultural appeal of its "high-altitude plant" positioning and single-brand model [6] - The journey of Plant Doctor's IPO signifies a broader trend in the Chinese cosmetics industry towards high-quality development, emphasizing brand value and operational focus [6]

天眼查App显示，近日，四川悦颜美化妆品有限公司成立，法定代表人为王义才，注册资本10万人民 币，经营范围为一般项目：化妆品零售；化妆品批发；日用品销售；日用百货销售；食品互联网销售 （仅销售预包装食品）；食品销售（仅销售预包装食品）；互联网销售（除销售需要许可的商品）；母 婴用品销售；办公用品销售；文具用品零售。（除依法须经批准的项目外，凭营业执照依法自主开展经 营活动）许可项目：生活美容服务。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具 体经营项目以相关部门批准文件或许可证件为准）。 ...

Core Viewpoint - The IPO review status of Beijing Plant Doctor Cosmetics Co., Ltd. has been updated to "inquired," marking a critical stage in its journey to list on the Shenzhen Stock Exchange, representing a significant leap for a Chinese brand rooted in technology and culture to go global [1] Group 1: Brand Philosophy and Strategy - The brand's philosophy is deeply influenced by the wisdom of the Naxi ethnic group's herbal medicine, emphasizing the use of natural plant resources for skincare [3] - Plant Doctor has established a differentiated strategy by combining traditional high-altitude plant resources with modern skincare technology, creating a unique path for "Chinese brand, Chinese ingredients" [3] - The brand has successfully built a strong image of being natural, safe, and effective in the minds of global consumers, laying a solid foundation for market expansion [3] Group 2: Research and Development - The company has established the "Chinese Academy of Sciences Kunming Plant Research Institute Plant Doctor R&D Center," which serves as the cornerstone of its research capabilities [3] - Plant Doctor has developed a global R&D network with a structure of "one center, five bases," covering various locations including Beijing, Kunming, Shunde, Wuxi, and Tokyo, ensuring a complete closed-loop from basic research to industrial application [3] - The innovative transformation of large molecular Dendrobium polysaccharides into more absorbable Dendrobium oligosaccharides exemplifies the company's strong R&D capabilities, contributing to the success of its flagship product series with annual sales exceeding 5.8 billion yuan [5][6] Group 3: Market Presence and Sales Channels - Plant Doctor has adopted a unique channel model that deeply integrates products and services, focusing on offline chain operations rather than relying solely on online traffic [6] - As of June 2025, the company has over 4,200 single-brand stores globally, serving more than 30 million members across multiple countries and regions [6] - The brand has been recognized as a leader in the beauty and body care industry in China for three consecutive years and has received certification as a "global leader in single-brand skincare specialty stores" from Euromonitor International since 2023 [6] Group 4: Global Expansion and Corporate Responsibility - The company has made steady progress in its global expansion, with successful entries into markets such as Japan, Singapore, and Thailand, showcasing its vision of making the world love Chinese cosmetics [8] - Plant Doctor adheres to the philosophy of respecting nature, valuing science, and giving back to society, aligning its actions with the goals of the United Nations Development Programme (UNDP) [8] - The funds raised from the IPO will be used to enhance R&D innovation, upgrade brand image, and expand global marketing channels, positioning the company as a cultural ambassador and a responsible enterprise [8]

国家药监局综合司关于印发化妆品企业生产质量管理体系提升三年行动计划(2026—2028年)的通知 药监综妆〔2025〕70号 各省、自治区、直辖市和新疆生产建设兵团药品监督管理局： 现将《化妆品企业生产质量管理体系提升三年行动计划(2026—2028年)》印发给你们，请结合实际，认 真贯彻落实。 国家药监局综合司 据"国家药监局"微信公众号消息，国家药监局近日发布《国家药监局综合司关于印发化妆品企业生产质 量管理体系提升三年行动计划(2026—2028年)的通知》。内容如下： 3.提升关键岗位人员履职能力。药品监管部门要压实化妆品企业质量安全主体责任，强化关键岗位人员 责任意识。在日常监管中，将企业落实化妆品质量安全责任制、关键岗位人员履职情况等纳入监督检查 重点。要因地制宜创新监管方式，强化关键岗位人员培训宣贯、抽查考核等工作的力度。鼓励行业协会 开展面向化妆品企业负责人、关键岗位人员的质量管理公益培训，督促指导企业不断提升质量管理意 识。 2025年12月8日 化妆品企业生产质量管理体系提升三年行动计划(2026—2028年) 体系管理是化妆品质量安全管理的精髓和要义，过程安全是产品安全的先决条件。化妆品 ...

天眼查App显示，近日，深圳思诺琪珠宝有限公司成立，法定代表人为廖丹丹，注册资本50万人民币， 经营范围为一般经营项目是：珠宝首饰制造；珠宝首饰批发；珠宝首饰零售；珠宝首饰回收修理服务； 互联网销售（除销售需要许可的商品）；工艺美术品及礼仪用品销售（象牙及其制品除外）；工艺美术 品及礼仪用品制造（象牙及其制品除外）；有色金属压延加工；钟表销售；眼镜销售（不含隐形眼 镜）；工艺美术品及收藏品零售（象牙及其制品除外）；专业设计服务；化妆品批发；化妆品零售；卫 生用品和一次性使用医疗用品销售；服装服饰批发；服装服饰零售；箱包销售；鞋帽批发；鞋帽零售； 货物进出口；技术进出口；进出口代理；国内贸易代理；销售代理；信息咨询服务（不含许可类信息咨 询服务）；市场营销策划。（除依法须经批准的项目外，凭营业执照依法自主开展经营活动），许可经 营项目是：无。 ...

Group 1: A-Share Market Overview - On December 12, A-share market indices showed mixed performance, with the Shanghai Composite Index slightly down by 0.04%, while the Shenzhen Component Index rose by 0.57% and the ChiNext Index increased by 0.6% [2] - The sectors that performed well included nuclear fusion, nuclear power, ultra-high voltage, and superconducting concepts, with their respective indices rising over 3% [2] Group 2: Nuclear Power Sector - The nuclear power sector experienced a significant increase, with the concept index rising by 3.17%, and over 4 billion yuan of main funds flowing into the sector [3] - Key stocks such as Sun Cable, Zhongchao Holdings, and Changcheng Electric reached their daily limit, with Sun Cable seeing over 116 million shares bought at a total of over 1.2 billion yuan [3] - Recent achievements in China's nuclear power projects include the successful grid connection of the world's largest "Hualong One" nuclear power base and the initiation of construction at the Shandong Zhaoyuan nuclear power base [3] Group 3: Cosmetics Industry Developments - The National Medical Products Administration (NMPA) released a three-year action plan aimed at enhancing the production quality management system for cosmetics from 2026 to 2028, encouraging innovation in quality management and the adoption of intelligent production methods [5] - As of now, China has transitioned from a major cosmetics producer to a strong player in the industry, with over 230,000 registered products and a market share of domestic cosmetics exceeding 55.2% [6] - The cosmetics market in China is projected to maintain a trillion-yuan scale in 2024, with over 5,700 companies in the sector [6] Group 4: Financial Performance of Cosmetics Companies - Among the 47 A-share companies involved in the cosmetics industry, 18 reported a year-on-year increase in net profit for the first three quarters, with notable growth from companies like Fujilai and Qingsong Co., with increases of 430.16% and 246.98% respectively [7][8] - A total of 12 companies saw an increase in R&D expenses, with Shiang Technology reporting a record high R&D expenditure of 29.13 million yuan for the first three quarters [8] - Financing activity has been robust, with 16 stocks receiving net inflows since December, led by companies like Lihua Kechuang and Aimeike [8]